Stay updated on IO102/IO103 Combo + Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the IO102/IO103 Combo + Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the IO102/IO103 Combo + Pembrolizumab in Melanoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedA new revision entry 'Revision: v3.5.4' has been added to the history, replacing the previous revision tag. This documents the latest update to the study record's revision metadata.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check31 days agoChange DetectedThe page’s UI revision indicator was updated from v3.5.2 to v3.5.3, reflecting a software/version change for the ClinicalTrials.gov record history display.SummaryDifference0.1%

- Check38 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0 in the study record history.SummaryDifference0.1%

- Check45 days agoChange DetectedAdded a new 'Results Submission Events' section to the study record history, displaying events related to results submission.SummaryDifference0.1%

- Check67 days agoChange DetectedRecord History now includes new data sections (Outcome Measures, Adverse Events, Baseline Characteristics, Participant Flow) and a Quality Control status. It also notes a new revision (Revision: v3.5.0) with the date 2026-03-12.SummaryDifference1.0%

- Check74 days agoChange DetectedAdded revision note for v3.4.3 and removed v3.4.2 from the page's version history.SummaryDifference0.1%

Stay in the know with updates to IO102/IO103 Combo + Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IO102/IO103 Combo + Pembrolizumab in Melanoma Clinical Trial page.